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CHAPTER I 
INTRODUCTION 
 Designing formulations and delivery systems for topically applied ophthalmic 
drugs is challenging. The search for novel ways of delivering therapeutically active 
agents has been the focus of attention in the past 2 to 3 decades. For any noninvasive 
route of administration, the need to prolong the duration of residence of the dosage form 
is evident. This is especially true in the area of ophthalmic drug delivery. 
  An effective ocular drug delivery device must be easy to use, comfortable to the 
patient and must improve the therapeutic performance of the drug over conventional 
dosage forms.1 Some ocular diseases may be treated by systemic dosage forms, either by 
oral ingestion or parenteral injections, however the systemic routes presents the great 
disadvantage of exposing all organs of the body to the action of the drug, thus leading to 
the unwanted side effects.2 
  Topical application of drugs to the eye is the most popular and well accepted 
route of administration for the treatment of various eye disorders.3 Except skin, the eye is 
the most easily accessible site for topical administration of a medication.4 Various 
systems have been designed to maximize ocular absorption of ophthalmic drugs. There 
are two main strategies for improvements, increasing the corneal permeability and 
prolonging the contact time on the ocular surface. Formulations were maximizing the 
absorption through prolongation of the drug residence time in the conjunctival sac.5
 Drugs are commonly applied to the eye for a localized action, on the surface, or in 
the interior of the eye. Poor bioavailability of drugs from ocular dosage forms is mainly 
due to the precorneal loss factors which include tear dynamics, non-productive 
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absorption, transient residence time in the cul-de-sac, and the relative impermeability of 
the corneal epithelial membrane.  
            Due to these physiological and anatomical constraints only a small fraction of the 
drug is ocularly absorbed. The effective dose of medication administered ophthalmically 
may be altered by varying the strength, volume, or frequency of administration of the 
medication or the retention time of medication in contact with the surface of the eye.  So 
far, attempts have been made to improve ocular drug bioavailability by extending drug 
residence time in the conjunctival sac and improving drug penetration across the cornea, 
the major pathway of drug entry into the internal eye.  
 
 TOPICAL OCULAR DRUG DELIVERY AND THE CONSTRAINTS     
  TO OCULAR THERAPY 
            For ailments of the eye, topical administration is usually preferred over systemic 
administration for obvious reasons:  
• The systemic toxicity of many ophthalmic drugs,  
• The rapid onset of action, and  
• The smaller dose required compared to the systemic route.  
            The topically applied ocular drugs have to reach inner parts of the eye to elicit 
responses. The trans-corneal penetration is believed to be the major route for drug 
absorption. Most ocular drugs seem to penetrate the cornea by diffusion. The paracellular 
(i.e.,through intercellular space) and the transcellular pathways (i.e., through intracellular 
space) are the two mechanisms for drug transport across the cornea. 
            The cornea is divided into five layers (the epithelium, Bowman’s membrane, the 
substantia propria or the stroma, Descemet’s membrane, and the endothelium). The 
epithelium and the endothelium are rich in lipids; on the other hand, the stroma has high 
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water content. The epithelium is reported to be the rate-limiting barrier to transcorneal 
transport. Its barrier function depends favorably on the lipophilicity of molecules and 
excludes the macromolecules (r>10 A°). The corneal epithelium is a layered structure of 
50–100 mm thickness. These cells have skirting intercellular junctions, termed ‘‘tight 
junctions,’’ forming a strong barrier.4 
 
Ocular pharmacokinetics: barriers in drug delivery  
The ocular tissues can be reached either by local or systemic drug administration. 
The tissue barriers limit the access of drugs to their targets (Figure). The blood–aqueous 
barrier, composed of the uveal capillary endothelia and ciliary epithelia, limits the access 
of compounds from the systemic circulation to the anterior chamber, whereas the blood–
retina barrier limits the drug diffusion from the systemic blood to the retina and vice 
versa. 
 
 
Chapter I                                                                                                           Introduction       
 
4
 
            The barrier has two components: outer and inner blood–retina barriers that are 
formed by the retinal pigment epithelium (RPE) and the tight retinal capillary walls, 
respectively.6 
 
PATHOLOGIES OF OCULAR SYSTEM 
 The pathologies of ocular system can be divided into topically treated pathologies 
and intraocular pathologies 
OCULAR PATHOLOGIES 
  
 
Topically Treated Pathologies                                              Intraocular pathologies 
(i) Inflammations                 (i) Glaucoma Filtering Surgery failure   
(ii) Keratoconjuctivities sicca              (ii) Proliferative vitreoretino  pathy                
(iii) Glaucoma                           (iii) Cytomegalovirus retinitis 
                                                                        (iv) Endopththalmitis 
                              (v)  Posterior uveitis 
                                      (vi) Posterior capsule opacification 
                                                                         (vii) Retinal Degenerative disease 
These are all the various major pathologies involved in the ocular system.2 
Chapter I                                                                                                           Introduction       
 
5
REASONS FOR POOR BIOAVAILABILITY OF OCULAR PREARATIONS 
• Poor ocular drug bioavailability is the result of ocular anatomical and 
physiological constraints, which include the relative impermeability of the corneal 
epithelial membrane, tear dynamics and nasolacrimal drainage.7 
• Most of the topically applied drugs are washed off from the eye by various 
mechanisms include lacrimation, tear dilution and tear turn over resulting in low 
ocular bioavailability of drugs.8 
• The residence time of most conventional ocular solutions ranges between 5 and 
25 minutes. Only 1-10% of topically applied drug is absorbed.9 
• The corneal epithelium is the main barrier of drug absorption into the eye. 
•  Only few percent of the applied dose is delivered into ocular tissues, the major 
part of the dose absorbed systemically. 
• The systemic absorption of ocularly applied drug is nearly complete. 
• This has caused systemic side effects varying from mild to life threatening 
events.5 
• Systemic absorption can be minimized by,  
A) Reducing the instilled volume,       B) Controlling drug release,  
C) Prodrug derivatization,                    D) Adding vasoconstrictive agents  
These are all the reasons for poor bioavailability.9 
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VARIOUS APPROACHES INVOLVED IN OCULAR DRUG DELIVERY 
SYSTEM 
Ophthalmic Solutions 
            Ophthalmic solutions are the most common dosage form for delivering 
drugs to the eye. These are used for soluble drugs, require frequent instillation of highly 
concentrated solutions.10 More than 90% of the marketed ophthalmic formulations are in 
the form of eye drops.8 
Advantages 
a) Cost effective 
b) Greater simplicity of formulation development and production  
c) Good acceptance by patients10  
Disadvantages  
a) Poor ocular drug bioavailability 
b) Pulse drug entry  after topical administration 
c) Systemic exposure because of nasolacrimal duct drainage 
d) Frequent instillation of eye drops results in local side effects such as, 
• Head ache due to ciliary muscle spasm 
• Decreased vision in poor illumination due to miosis & accommodative 
myopia.11 
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OPHTHALMIC SUSPENSIONS 
            Suspensions are dispersions of finely divided, relatively insoluble, drug 
substances in aqueous vehicle containing suitable suspending and dispersing agent. 
Advantages 
a) The contact time and duration of action exceed that of a solution  
b) Good acceptance by the patients   
Disadvantages  
a) Brisk shaking is always required to distribute the suspended particles before each 
use 
b) Suspension favours the phenomenon of polymorphism, due to crystal growth 
chances for increased or decreased bioavailability 
c) Blurred vision 
OPHTHALMIC OINTMENTS 
            Ophthalmic ointments are primarily anhydrous and contain mineral oil and 
white petroleum as the base. Dosage availability of ophthalmic ointments is probably 
greater than the solutions. 
Advantages 
a) Longer contact time and greater total drug bioavailability 
b) Popular as a pediatric dosage form and for post operative use 
Chapter I                                                                                                           Introduction       
 
8
Disadvantages  
a) Blurred vision due to greasy nature  
b) Due to interference with the vision their use is usually limited to bed time 
instillation 
c) Moisture sensitive drugs cannot be formulated as ointment10 
OPHTHALMIC GELS 
                 Ophthalmic gel formation is an extreme case of viscosity enhancement 
through the use of viscosity enhancers. Despite extremely high viscosity gels achieve 
only limited improvement in bioavailability. 
Advantages  
a) Increased bioavailability than solutions.  
b) Dosing frequency is less to once a day at most. 
Disadvantages  
a) Blurred eye vision and matted eye lids 
b) Reduced patient acceptability7 
OCULAR INSERTS 
           Ocular inserts have been developed in which the drug is delivered on the 
basis of diffusional mechanism. Such a solid dosage form delivers an ophthalmic drug at 
a near constant know rate, minimizing side effects by avoiding excessive absorption 
peaks. 
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Advantages 
a) Ocusert gives sustained or controlled drug release 
Disadvantages 
a) Self administration is so difficult 
b) Foreign body sensation  
c) Inadvertent loss from the eye 
d) Rupture of its membrane causing excessive bolus drug release.12 
PENETRATON ENHANCERS 
           In the early stages of ophthalmic drug delivery research, chelating agents, 
preservatives, surfactants and bile salts were studied as possible penetration enhancers. 
Advantages 
a) Enhanced corneal drug penetration 
Disadvantages 
a) ocular irritation and toxicity 
PRODRUGS 
           The principle of prodrug is to enhance corneal drug permeability through 
modification of the hydrophilic of the drug. 
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Advantages 
a) Enhanced corneal drug penetration 
Disadvantages 
a) Difficult to design and develop7 
LIPOSOMES 
            The use of liposomes as a topically administered ocular drug delivery 
system began in the early stages of research in to ophthalmic drug delivery. The results 
were favourable for lipophilic drugs, but disappointing for hydrophilic drugs.     
Advantages 
a) droppable, biocompatible, biodegradable 
b) potential for bioavailability improvement 
c) toxicity reduction 
d) sustained release and site specific delivery13 
Disadvantages 
a) low drug loading 
b) Inadequate aqueous stability 
c) Manufacturing difficulties for sterile preparations.7 
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IN SITU-FORMING GELS 
          In situ forming hydrogels are liquids upon instillation and undergo a phase 
transition to form a viscoelastic gel in response to environmental changes like 
temperature, pH and electrolyte composition.14 
Advantages  
a) In situ forming hydrogels are attractive as conventional ocular solutions because 
of facile dosing as a liquid 
b) Ensures complete and rapid ocular coverage 
c) They also allow for accurate and reproducible quantities to be administered to the 
eye in contrast to pre-gelled formulations2 
d) Prolonged contact time and increased bioavailability 
e) Improved level of patient acceptance 
f) Once or twice day dosing is the great advantage14
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CHAPTER III 
LITERATURE REVIEW 
 
1. Srividya et al., studied a sol-to-gel ophthalmic delivery system of ofloxacin based 
on PH-triggered in situ gelation using poly(acrylic acid) (Carbopol940) in 
combination with HPMC (Methocei E50LV) and showed the system was 
therapeutically efficacious,stable,non-irritant and provided sustained release over 
8-hour period. 
 
2. Naseem A. et al., reported sol-to-gel system of ciprofloxacin hydrochloride using 
HPMC (K15M) and carbopol 940 and showed the system was active against 
selected microorganism compared with marketed for more than 2 years. 
 
 
3. Zhidong Liu et al., evaluated the in situ gel forming system based on ion 
activated gelation by using HPMC(E50LV) and alginate and showed 
alginate/HPMC mixture can be used as an in situ gelling vehicle to enhance ocular  
bioavailability and patient compliance. 
 
4. Raida S.et al., designed a controlled release sol-to-gel ophthalmic delivery 
system for ciprofloxacin with HPMC and methyl cellulose combined with 
carbopol to increase the viscosity of the gels and the formulation showed increase 
in viscosity,gelling capacity and efficiency against gram positive and gram 
negative organism including E.coli,Staphylococcus and Pseudomonas aeruginosa 
and also showed its prolonged antimicrobial activity. 
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5. Mai Mansour et al., prepared in situ forming hydrogel using 
Poloxamer407(P407) and Poloxamer 188(P188) HPMC or HEC and evaluated for 
in vitro drug release ,sol-to-gel transition temperature,rheological behaviour and 
showed optimum release and improved ocular bioavailability when compared to 
marketed conventional eye drops. 
 
6. Amel El-Kamel et al., prepared a environmentally responsive sol-to-gel 
formulation by using gelrite and showed pseudoplastic behaviour with thixotropic 
characteristics and the viscosity of the prepared system increased as the polymer 
concentration increases. Formulations containing gelrite and 1% drug showed 
significantly improved bioavailability compared with commercial aqueous 
preparation. 
 
 
7. Ega Chanra Mohan et al., prepared formulations of  an ophthalmic drug delivery 
system of an antibacterial agent, ciprofloxacin based on concepts of PH-triggered 
in situ gelation by using polyacrylic acid (Carbopol 940) in combination with 
HPMC ,thermo reversible gelation by using pluronic F-127 (14%) in combination 
with HPMC and ion activated system by using gellan gum and showed the 
developed system was therapeutically efficacious, stable, non irritant and  
sustained release. 
 
8. Mitan R. et al., prepared and developed a system of ophthalmic drug delivery 
system of model drug tropicamide based on the concept of pH-triggered in situ 
gelation. Polyacrylic acid(Carbopol 940) was used in combination with HPMC 
K15M and all formulation sterilized in an autoclave at 121◦C and 15 psi for 20 
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minutes. The system showed higher in vitro gelling capacity, exhibit pseudoplastic 
behaviour in both solution and gel and in vitro drug release of more than 8-hours. 
 
 
9. Sindhu Abraham et al., reported an ophthalmic delivery system of an 
antibacterial agent ofloxacin based on the ion activated in situ gelation.sodium 
alginate in combination with HPC was used. The release studies indicated that the 
alginate/HPC solution retained the drug better than the alginate or HPC solution 
alone and showed the developed system  were therapeutically efficacious, sterile, 
stable and provided sustained drug release. 
 
10. Jagadish balasubramaniam et al., developed an ophthalmic delivery system of 
the NSAID indomethacin based on ion activated in situ gelation.The developed 
formulations were therapeutically efficacious and provided in vitro release of drug 
over 8-hour  period in vitro. 
 
 
11. Doijad R.C, et al., reported an ophthalmic drug delivery system of an 
antibacterial agent gatifloxacin, based on the concept of ion activated system. 
Sodium alginate was used in combination with HPMC (E50LV) and showed 
therapeutically efficacious, stable, non-irritant formulations and provided 
sustained release of the drug over an 8-hour period. 
 
12. Sivanaga S. et al., studied pilocarpine loaded ocular hydrogels and demonstrated 
that in situ forming hydrogels posses the viscoelastic, and sustained delivery 
properties required for an efficient ocular drug delivery system. 
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13. Indu pal kaur et al., reported that incorporation of acetazolamide into in situ 
forming ophthalmic drug delivery system showed increase in residence time. 
 
14. Miyazaki S.et al., studied about the vehicles for ocular delivery and showed 
sustained release of all in situ gels over 6hrs period of time. 
 
15. Gang wei,et al., demonstrated three fold increase in corneal residence time of in 
situ gels. 
 
16. vandamme S.et al., studied ophthalmic vehicles for ocular delivery and showed 
prolonged drug residence time for ophthalmic route. 
 
17. Yasmin Sultana,M.et al., developed and characterized a series of carbopol and 
methyl cellulose solutions as the in situ gelling vehicle and reported the mixture of 
carbopol(0.3%) and methyl cellulose(1.5%) showed a significant enhancement in 
gel strength and showed the mixture can be used as an in situ gelling vehicle to 
enhance the ocular bioavailability. 
 
18. Chunjie Wu et al., developed a pH-triggered in situ gelling vehicle for 
ophthalmic delivery of puerarin. They demonstrated that in vitro release studies of 
combined polymer system of carbopol 980NF/HPMC E4M performed better in 
retaining capacity than conventional eye drops. 
 
19. Eun-young Kim.et al., studied the effect of poloxamer and showed the 
poloxamer gel could be applicable for the development of effective ophthalmic 
delivery. 
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20. Zhidong liu et al., demonstrated ion-activated in situ ophthalmic gel of 
gatifloxacin by microdialysis. The developed formulation has a higher 
bioavailability and longer residence time than ophthalmic solutions. 
 
21. Sathish kumar P.Jain,et al., reported ophthalmic delivery system for 
ciprofloxacin hydrochloride based on the concept of pH-triggered in situ gelation 
by using poly(acrylic acid)(Carbopol 980NF) as a phase transition polymer and 
HPMC(k100LV) as release retardant and reported the formulation was stable and 
non irritant to rabbit eyes and showed sustained in vitro release. 
 
22. Sibel Bozdag et al., demonstrated viscous solutions of cysteamine hydrochloride 
using HPMC and reported increased pH and increased viscosity and showed drug 
release for 8 hrs. No irritation was observed when the viscous solutions were 
tested on rabbit eye. 
 
23. Wen-Di Ma,et al., developed in situ gelling system of pluronic F127-g-
poly(acrylic acid) copolymer as a ophthalmic vehicle and showed significant 
increase in drug resident time and better rheological behaviour. 
 
24. Maria Cristina Bonferoni,et al., reported the ion-exchange based ophthalmic 
delivery system of carrageenan and showed increase in in vitro release. 
 
25. Odile Sechoy,et al., studied alginic acid ophthalmic solutions for prolonged drug 
release of carteolol and reported that alginic acid vehicle is an excellent drug 
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carrier and could be used for the development of a long-acting ophthalmic 
formulation of carteolol. 
 
26. Shivanand Swamy P.et al., demonstrated novel in situ gum based ophthalmic 
delivery system of linezolid and showed extended release of the formulation and 
non irritant to rabbit eyes. 
 
27. Katarina Edsman et al, studied carbopol 974P and 1342NF and showed better 
ocular residence time due to elastic property of the gel and rheological studies 
were satisfactory. 
 
28. Helene Hagerstrom,et al., reported the two ion sensitive polymers of carbopol 
934 and Gelrite (deacetylated gellan gum) and showed the rheological behaviour 
of both the polymer and the polymers were found to be have better rheological 
property. 
 
29. John Carlfors,et al., studied Gelrite in situ gels for in vivo study to determine 
precorneal residence time .They showed high rate of the sol/gel transition results 
in long contact time. 
 
30. Hong-Ru Lin,et al., demonstrated a series of carbopol and pluronic based 
solutions as the in situ gelling vehicle for ophthalmic delivery and the mixture of 
0.3% carbopol and 14.0% pluronic solution showed significant enhancement in 
gel strength and free flowing at pH 4.0 and 25◦C.The results showed that the 
carbopol/pluronic solutions had better ability to retain drug than the carbopol or 
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pluronic solutions alone and showed the mixture can be used as an in situ gelling 
vehicle to enhance the ocular bioavailability. 
 
31. Katarina Edsman,et al., developed the sol-to-gel transition of an in situ gel of 
Poloxamer 407 and showed the increase in corneal contact time when there is 
increase in Poloxamer concentration and the system was found to be temperature 
dependant. 
 
32. R.C.Doijad,et al., studied ophthalmic delivery system of an antibacterial 
agent,gatifloxacin, based on the ion activated system using sodium alginate and 
HPMC E50LV .The developed formulations were therapeutically 
efficacious,stable, non-irritant and provided sustained release of the drug over an 
8-h period of time. 
 
33. J.K.Pandit,et al studied the different types of in situ system of indomethacin and 
showed the formulated system was concentration dependant and the drug release 
was extended upto8-h and followed zero order kinetics. 
 
34. Hongyi Qia,et al., developed a thermosensitive in situ gelling and mucoadhesive 
ophthalmic drug delivery system containing puerarin based on poloxamer analogs 
(21% (w/v) poloxamer 407/5% (w/v) poloxamer 188) and carbopol (0.1% (w/v) or 
0.2% (w/v) carbopol 1342P NF).The in vitro release studies demonstrated 
diffusion-controlled release of puerarin from the combined solutions over a period 
of 8 hrs and showed ocular bioavailability can be increased. 
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35. Wu C,et al., developed a pH-triggered in situ gelling vehicle for ophthalmic 
delivery of puerarin in which Carbopol 980NF was used as the gelling agent in 
combination with HPMC (Methocel E4M) which acted as a viscosity-enhancing 
agent. The combined solution could flow freely under non- physiological 
condition and showed the character of pseudoplastic fluid under both conditions. 
Both in vitro release studies and in vivo pharmacokinetics studies indicated that 
the combined polymer systems performed better. Results demonstrate that the 
Carbopol 980NF/HPMC E4M can be a viable alternative to conventional puerarin 
eye drops to enhance ocular bioavailability and patient compliance.                      
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CHAPTER II 
IN SITU GELS - A REVIEW 
 A major problem in ocular therapeutics is the attainment of an optimal drug 
concentration at the site of action.15 Various systems have been designed during the past 
two decades to maximize ocular absorption of ophthalmic drug. 
   The various approaches attempted in the early stages can be divided in to two 
main categories. Bioavailability improvement and controlled release drug delivery.7                         
 A more desirable dosage form would be one that can be delivered in a drop form, 
creates little to no refractive index problem for vision.16 Current research efforts are 
focused towards the design and evaluation of ocular delivery systems that are easy to 
administer, require decreased administration frequency and provide controlled and 
possibly sustained release, to increase therapeutic efficacy and patient compliance.11 
 Major progress has been made by ophthalmic gel technology in the developent of 
droppable gels or Insitu forming gels.14 In the present era, sol-gel technolgy has the most 
promising applications in drug delivery systems as well as in industries17 Hydrogels are 
expected to provide prolonged corneal contact time, when used in ocular drug delivery 
system, and also provide reduced precorneal drug loss, convenience in administration as 
compared to eye drops, suspensions or ointments.11 
HYDROGELS 
             The most common way to improve drug retention on the corneal surface is by 
using polymers to increase solution viscosity. Hydrogels are cross linked network of 
hydrophilic polymers that have the ability to absorb large amounts of water and swell, 
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while maintaining their three dimensional structure. Molecules of different sizes can 
diffuse in and out of the hydrogel network, which allows their possible use as a drug 
depot for controlled release applications. 
             Hydrogels show minimum tendency to absorb protein from body fluids due to 
their low interfacial tension. They closely resemble living tissue due to their high water 
content and soft/rubbery characteristics. The viscoelastic properties of hydrogels 
should allow for sufficient mechanical strength to resist clearance due to blinking, 
resulting in prolonged ocular residence time.14  
Hydrogels: A brief overview   
            Hydrogels are a three-dimensional network of hydrophilic polymers held together 
by association bonds such as covalent bonds and weaker cohesive forces such as 
hydrogen and ionic bonds and intermolecular hydrophobic association.  
             These networks are able to retain a large quantity of water within their structure 
without dissolving. Due to their superior chemical and physical properties, hydrogels 
have received much attention for preparing drug delivery systems.  
             The elastic nature of the hydrated hydrogels when used as implants has been 
found to minimize irritation to surrounding tissue.  
             The low interfacial tension between the hydrogel surface and the aqueous 
solution has been found to minimize protein adsorption and cell adhesion.  
General Classification of Hydrogels:   
Source:  
1) Natural      2)   Synthetic 
Chapter II                                                                  In-Situ Gels – A Review 
 14
 
Component: 
• Homopolymer     
• Copolymer 
• Multipolymer 
 
      Preparation method:  
• Simultaneous polymerization 
• Crosslink of polymer 
 
Electric charge: 
• Nonion 
• Anion 
• Cation 
• Zwitter ion 
     Physical structure: 
• Amorphous 
• Semicrystaline 
• Hydrogen bonded 
• Crosslink Covalent bond 
• Intermolecular force 
 
Functions: 
• Biodegradable 
• Stimuli responsive 
• Superabsorbent 
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Fundamentals                                
     Wichterle and Lim introduced a type of hydrophobic gel for biological uses in 
the early 1960s.A huge sum of efforts and studies has been devoted to advancing and 
extending the potentials attributed to hydrogels. Ever-growing hydrogel technology has 
led to dramatic advances in pharmaceutical and biomedical era. 
             Due to the contribution of these groups and domains in the network, the polymer 
is thus hydrated to different degrees (sometimes, more than 90%wt.), depending on the 
nature of the aqueous environment and polymer composition.                                       
  
Properties:  
1. Water Content and Swelling Ratio  
             The polymer chains of hydrogels interact with the solvent molecule and tend to 
expand to the fully solvated state. On the other hand, the crosslink structure works as the 
re-tractive force to pull back the polymer chain inside. 
             This retractive force is described by the Flory rubber elasticity theory.To describe 
the swelling behavior of hydrogels, their swelling ratio or water content is currently used 
in most cases. The water content of a hydrogel is expressed in terms of percentage of 
water by weight:  
                                
 
  Weight of water ×100  
Water content = _______________________________      
                            Weight of water + weight of dry gel 
                        
   For instance, most of hydrogel contact lenses have water content between 38 and 
75%. When the water content of the hydrogel is over 90%, the hydrogel is called super 
adsorbent hydrogel.  Another index which characterizes hydrogels is the swelling ratio, 
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expressed by the ratio of the weight of swollen sample over that of the dry sample: 
Swelling ratio: weight of swollen gel / weight of dry gel 
 Peppas suggested that the swelling characteristic of hydrogels is a key for the use 
of hydrogels in biomedical and pharmaceutical applications, since the equilibrium 
swelling ratio influences the solute diffusion coefficient, surface wettability and mobility, 
and optical and mechanical properties of hydrogels. 
 
Permeability  
     The permeability of target molecules is of utmost importance for medical    
application of hydrogels. For instance, oxygen permeation for contact lens, nutrient and 
immunological biosubstance transport for immunoisolation, and releasing drugs and 
proteins for drug delivery systems are core characteristics for each application.18  
 
MECHANISIMS OF DRUG RELEASE FROM HYDROGELS 
             It involves a combination of diffusion and erosion of the gel surface. Due to 
hydrophilic nature of the gels, tears readily diffuse into the gel interior their by rapidly 
leaching out water soluble drugs. 
Release mechanism from hydrogel matrices  
             Since the most common mechanism of drug release from hydrogels is passive 
diffusion, molecules of different sizes and characteristics would freely diffuse into/out of 
hydrogel matrix during the loading and storage periods. The hydrophilic nature of a 
hydrogel makes it highly different from non-hydrophilic polymer matrices with respect to 
the release behavior of the incorporated agents.  
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Mechanisms of drug release from hydrogels can be categorized as: 
i) Diffusion-controlled  
ii) Swelling-controlled 
                                   iii)         Chemically-controlled 
   According to Fick's first law of diffusion (with constant or variable diffusion 
coefficients), the diffusion-controlled behavior is the most dominantly applicable 
mechanism to describe the drug release from hydrogels.  
             The drug diffusion out of a hydrogel matrix is primarily dependent on the mesh 
sizes within the matrix of the gel, which, in turn, is affected by several parameters, 
including, mainly, the degree of crosslinking, chemical structure of the composing 
monomers, and, when applicable, type as well as intensity of the external stimuli.   
 
DESIRED PROPETIES OF POLYMERS USED IN OPHTHALMIC 
HYDROGELS AS DRUG DELIVERY SYSTEMS 
• Chemical compatibility with the other excipients and the drug 
• Stability after prolonged storage and if possible heat stability permitting 
sterilization by autoclaving 
• Absence of ocular irritation or toxicity 
• Little or no problem for vision 
• Promotion of precorneal retention due to viscosity or bio adhesive properties. 
• Physicochemical properties (pH, osmolality) compatible with the ocular use. 
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CLASSIFICATION OF HDROGELS USED IN OPHTHALMOLOGY  
  Polymeric hydrogels used in ophthalmology are generally classified into two 
different groups. 
  
 
 
 Both systems has different method of preparation and different in their activity. 
PREFORMED HYDROGELS 
  These are systems which are administered as viscous preparations which do not 
under go any other transformation on the eye such as an eventual dilution by lacrimation 
or gradual elimination by lacrimal drainage, these hydrogels are called preformed gels 
and they are structured before ocular application. 
 
METHODS OF LOADING OF HYDROGELS AS DRUG CARIERS   
  In this method the hydrogel monomer is polymerized in the presence of the drug 
by addition of chemicals (initiator) and cross linker, so that the drug remains trapped in 
the polymeric matrix. 
Disadvantage 
 In some polymerization conditions may have deleterious effects on the drug and 
some chemicals are toxic.     
 
Preformed Gels 
 
HYDROGELS 
Insitu Activated 
Gel forming 
system 
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VARIOUS TYPES OF PREFORMED HYDROGELS 
Cellulose derivatives 
  Semi synthetic water soluble cellulosic polymers have been widely used in 
ophthalmic preparations such as eye drops, artificial tears and contact lens solutions as 
viscosity increasing agents. 
 The main cellulosic compounds used in ocular preparations include 
• Hydroxy ethyl cellulose 
• Hydroxy propyl cellulose 
• Hydroxy propy methyl cellulose 
• Sodium carboxy methyl cellulose 
The common properties of above polymers are,  
• Wide range of viscosity  
• Good ocular tolerance 
 
POLY ACRYLIC ACID 
  Polyacrylic acids also called carbomers or carboxy vinyl polymers, are acrylic 
acid based polymers which are available in different molecular weights and different 
structures. 
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SODIUM HYALURONATE 
  Hyaluronic acid is high molecular weight linear unbranched polysaccharide 
consists of repeating disaccharide units of glucuronid acid and N-acetyl glucosamine. 
POLYVINYL ALCOHOLS 
  Polyvinyl alcohols are synthetic long chain polymer obtained by condensation of 
vinyl acetate and partial or full hydrolysis of the resulting polyvinyl acetate. 
INSITU FORMING HYDROGELS 
 Insitu forming hydrogels are liquid upon instillation and undergo phase transition 
in the cul-de-sac to form viscoelastic gel and this provides a response to environmental 
changes.  
METHODS OF LOADING OF HYDROGELS AS DRUG CARIERS   
             In this method, a polymer is allowed to swell in a suitable drug solution or he 
drug is added to a preformed hydrogel and diffuses through the polymeric network. 
Advantages of in situ forming hydrogels 
• Prolonging the corneal contact time of the drug and decreasing its drainage rate, 
thus increasing ocular bioavailability. 
• It lowers the frictional resistance between the cornea and eyelids during blinking, 
there by exerting a lubricating effect. 
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Three methods have been employed to cause phase transition. 
(i) Gelling triggered by change in pH 
(ii) Gelling triggered by change in temperature 
(iii) Gelling triggered by change in ionic strength2      
GELLING TRIGGERED BY CHANGE IN pH  
 The concept of using hydrogels based on pH sensitive polymers for the ocular 
route began in the 1980s. These hydrogels are based on latex and carbomer. 
LATEXES 
            The term latex defines a low viscosity, stable polymeric dispersion of particles 
generally in an aqueous solvent. 
            Pseudo latexes are pH sensitive aqueous colloidal dispersion which undergo 
spontaneous coagulation and gellation after instillation in the conjunctival cul-de-sac 
because of pH increase.A change in pH is the most useful signal in the human body, 
because variation in pH occurs naturally in some areas of the body. In general, such pH-
responsive hydrogels can be prepared by using polymers with ionizable groups.  
            Drug release systems controlled by pH-responsive swelling can be developed, 
which exhibit zero-order or near-zero-order release of the incorporated drug. 
           The special hydrogels were sensitive to both temperature and pH, and respond to 
the pH change to a much greater extent than normal hydrogels with carboxyl groups. 
Only a negligible amount of indomethacin as a model drug was released at pH 1.4, while 
more than 90% of the total drug in the gels was released at pH 7.4.  
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       The swelling ratio of the hydrogels with the phosphate groups increased steeply 
at pH 5 and 10 because the phosphate group acts as an acidic charged divalent group. 
Furthermore, the hydrogels with the phosphate groups also showed swelling changes in 
response to temperature and solvent composition.19 
 
 
 
PREREQUISITES NECESSARY FOR OPTIMAL FORMULATION OF 
OPHTHALMIC PSEDUO LATEX 
• Solubility of the polymer in organic solvents and insolubility in water 
• Existence on the macromolecule of ionizable groups, which can react with the 
electrolytes of the lacrimal fluid. 
• Use of high molecular weight polymer 
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• Compatibility of the different components of the colloidal dispersion with 
precorneal tissues.2 
CELLULOSE ACETATE PHTHALATE LATEX (CAP-Latex) 
 The ability of CAP latex to be free running solution at pH4.2 and a gel at 7.2, and 
finally, the latex stable at low pH. 
CARBOMER 
 Cross linked Poly(acrylic acid) of high molecular weight, commercially available 
as carbopol, is widely used in ophthalmology to enhance precorneal retention to the eye.                      
Four mechanisms of interaction between mucin and poly(acrylic acid) have been 
described: electrostatic interaction, hydrogen bonding, hydrophobic interaction, and inter-
diffusion. 
            These mechanisms can be explained by the similar features of the mucus network 
and the cross-linked poly (acrylic acid): macromolecular expanded network, negative 
charges, and significant hydration in aqueous media and significant number of carboxyl 
groups. As the concentration of Carbopol increases in the vehicle, its acidic nature may 
cause stimulation to the eye tissues. In order to reduce the total polymer content and 
improve the gelling properties, an ocular drug delivery system based on a combination of 
Carbopol and methylcellulose has been developed.  
            Carbopol is a poly(acrylic acid)[PAA] polymer, which shows a sol to gel 
transition in aqueous solution as the pH is raised above its pKa of about 5.5. 
Methylcellulose, a viscosity enhancing polymer, exhibits a sol to gel transition in aqueous 
solution in the range of 50–55 °C. The rheological properties of this system were 
investigated and sol to gel transition occurred primarily by an increase in pH due to the 
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presence of Carbopol; the temperature-mediated effect occurred only at very low shear 
rates.  
            The development of a similar delivery system by the combinations of Carbopol 
and hydroxypropylmethylcellulose, For both systems it was found that a reduction in the 
Carbopol concentration without compromising the in situ gelling properties as well as 
overall rheological behaviors can be achieved by adding a suitable viscosity enhancing 
polymer.14 
GELLING TRIGGERED BY CHANGE IN TEMPERATURE 
            In this system, the drugs were released rapidly from the hydrogels due to the 
squeeze effect by their collapse as soon as the hydrogels were transferred from an 
aqueous solution below LCST (Lower critical solution temperature) to the release media 
above LCST.  
As the temperature-responsive hydrogels were swollen at a low temperature, the 
drug could be released from the hydrogels. However, when the temperature increased 
beyond their LCST, dense skin formation during the deswelling process stopped the 
release of the drug. 19,20,21 
Temperature induced gelation  
            These hydrogels are liquid at room temperature (20–25 °C) and undergo gelation 
when in contact with body fluids (35– 37 °C), due to an increase in temperature. Different 
thermal setting gels have been described in this review, including for example 
Poloxamers, cellulose derivatives, and xyloglucan. 
 
 
Chapter II                                                                  In-Situ Gels – A Review 
 25
Poloxamers (Pluronic®)  
            The Poloxamers consist of more than 30 different non-ionic surface active agents. 
These polymers are ABA-type triblock copolymers composed of polyethylene oxide 
(PEO) (A) and polypropylene oxide (PPO) units (B).  
 
            The Poloxamer series covers a range of liquids, pastes, and solids, with molecular 
weights and ethylene oxide–propylene oxide weight ratios varying from 1100 to 14,000 
and 1:9 to 8:2, respectively. Poloxamers, commercially available as Pluronic®, are the 
most commonly used thermal setting polymers in ophthalmology.  
            They are formed by central hydrophobic part (polyoxypropylene) surrounded by 
hydrophilic part (ethylene oxide). Depending on the ratio and the distribution along the 
chain of the hydrophobic and hydrophilic subunits, several molecular weights are 
available, leading to different gelation properties. Pluronic F-127, which gives colorless 
and transparent gels, is the most commonly used polymer in pharmaceutical technology. 
      Poloxamers have been widely investigated as ocular drug delivery systems At 
room temperature (b25 °C), the solution behaves as a mobile viscous liquid, which is 
transformed into a semisolid transparent gel at body temperature (37 °C). 
Cellulose derivatives  
      Thermo reversible gels can be prepared with naturally occurring polymers. Most 
natural polymer aqueous solutions form a gel phase when their temperature is lowered. 
Classic examples of natural polymers exhibiting a sol–gel transition include gelatin and 
carrageenan. At elevated temperatures, these polymers adopt a random coil conformation 
in solution. Upon cooling, a continuous network is formed by partial helix formation.  
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        Some cellulose derivatives are an exception to this gelation mechanism. At low 
concentrations (1–10 wt. %), liquid at low temperature, but gel upon heating. 
Methylcellulose and hydroxypropyl methylcellulose (HPMC) are typical examples of 
such polymers. Methylcellulose solutions transform into opaque gels between 40 and 50 
°C, whereas HPMC shows phase transition between 75 and 90 °C.  
          These phase transition temperatures can be lowered by chemical or physical 
modifications. For example, NaCl decreases the transition temperature of methylcellulose 
solutions to 32–34 °C. Similarly, by reducing the hydroxypropyl molar substitution of 
HPMC, its transition temperature can be lowered to ~40 °C. Gelation of methylcellulose 
or HPMC solutions is primarily caused by the hydrophobic interaction between molecules 
containing methoxy substitution.                
      
Xyloglucan  
Xyloglucan is the principal hemicellulose of primary cell walls of dicots and in 
about half of the monocots. It is structurally related to cellulose as it shares the same 
backbone of ß (1 .4)-linked glucose residues. The main repeating unit contains four 
glucose units. Three out of four glucose units are substituted with a (1 .6) xylose residues. 
Some xylose units are further substituted by galactose through a ß (1 .2) bond. In addition 
to these sugar units, the galactose residues can be further substituted with a (1 .2) fucose.  
 
The XG side chains give raise to radically different physical properties of the 
polymer compared to cellulose; xyloglucan is highly water soluble and cannot form 
ordered crystalline microfibrils as cellulose.  
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Xyloglucan, a polysaccharide derived from tamarind seed, forms 
thermoresponsive gels in water, under certain conditions. Xyloglucan is composed of a 
(1-4)-ß-Dglucan backbone chain (GLU) which presents (1-6)-a-D-xylose branches (XYL) 
partially substituted by (1-2)-ß-D-galactoxylose (GAL). 
     
    The transition temperature is inversely related to polymer concentration and the 
galactose removal ratio. For example, the sol–gel transition of xyloglucan was shown to 
decrease from 40 to 5 °C when the galactose removal ratio increased from 35 to 58%.  
GELLING TRIGGERED BY CHANGE IN IONIC STRENGTH 
            In this method, gelling of the solution instilled is triggered by change in the ionic 
strength. 
Gelrite: 
            Gellan gum (Gelrite) is a linear, anionic heteropolysaccharide secreted by the 
microbe Sphingomonas elodea (formerly known as Pseudomonas elodea).The 
polysaccharide can be produced by aerobic fermentation and then isolated from the 
fermentation broth by alcohol precipitation.  
   The polymer backbone consists of glucose, glucuronic acid, and rhamnose in the 
molar ratio 2:1:1. These are linked together to give a  tetrasaccharide repeat unit. The 
native polysaccharide is partially esterified with L-glycerate and acetate, but the 
commercial product Gelrite has been completely de-esterified by alkali treatment. 
Gelrite® (deacetylated gellan gum) is one of the most interesting in situ gelling polymers 
that has been tested since it seems to perform very well in humans.  
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       Gelrite forms double helices at room temperature. This solution has a viscosity 
close to that of water and the helices are only weakly associated with each other (by van 
der Waals attraction). When gel-promoting cations are present, some of the helices 
associate into cation-mediated aggregates, which cross-link the polymer. 
       Gelrite has also provided corneal residence times superior to those of other 
hydrogel preparations based on polymers such as cellulosic derivatives or xanthan gum. 
The rheological properties of gellan gum such as thixotropy, pseudoplasticity, and 
thermoplasticity are further advantages for its use in ophthalmology: the fluidity of the 
solution can be increased simply by shaking or slightly warming the preparation.                                      
 
Alginates  
        Being a family of unbranched binary copolymers, alginates consist of (1 .4) 
linked ß-D-mannuronic acid (M) and a-Lguluronic acid (G) residues of widely varying 
composition and sequence. By partial acid hydrolysis, alginate was separated into three 
fractions. Two of these contained almost homopolymeric molecules of G and M, 
respectively, while a third fraction consisted of nearly equal proportions of both 
monomers and was shown to contain a large number of MG dimer residues. 
       The alginate forms 3-dimensional ionotropic hydrogel matrices, generally by the 
preferential interaction of calcium ions with the G moieties resulting in the formation of 
inhomogeneous gel. Calcium-crosslinked alginate gels have shown good mechanical 
properties even when prepared from relatively low solution concentrations of the 
polymer, ~0.5% w/v, and they can physically entrap a whole array of molecules, and 
sustain their release.  
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Advantages of in-situ gelling system: 
 
In situ forming hydrogels are attractive as conventional ocular solutions because 
of facile dosing as a liquid. Ensures complete and rapid ocular coverage. They also allow 
for accurate and reproducible quantities to be administered to the eye in contrast to pre-
gelled formulations.2 Prolonged contact time and increased bioavailability. Improved 
level of patient acceptance. Once or twice day dosing is the great advantage14 
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CHAPTER IV 
AIM OF WORK 
           The ocular drug delivery has remained as one of the most challenging task for 
pharmaceutical scientists. 
The unique structure of the eye restricts the entry of drug molecules at the 
required site of action. Conventional systems like eye drops, suspensions and 
ointments cannot be considered optimal in the treatment of vision threatening ocular 
diseases.8 
The bioavailability is very poor when given in the form of ophthalmic 
solutions due to efficient productive mechanisms of the eye. There are more than 90% 
of the formulations available as ocular solutions. Frequent instillations of eye drops 
are necessary to maintain a therapeutic drug level in the tear film or at site of action. 
But, the frequent use of highly concentrated solutions may induce toxic side effects 
and cellular damage at the ocular surfac3 
The typical pulse entry type drug release observed with conventional 
preparations can be replaced by a more controlled, sustained and continuous drug 
delivery using a controlled release ocular drug delivery system. 
These systems can achieve therapeutic action with a smaller dose and a fewer 
systemic and ocular side effects, such systems include implants, ocuserts, collagen 
shields, nanoparticles, microspheres and liposomes, but the limitations of the above 
systems are 
• Poor patient compliance and difficulty of insertion in ocular inserts. 
• Tissue irritation and damage caused by penetration enhancers and 
collagen shields. 
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• Toxicity caused by insertion of foreign substances like albumin and 
poly butyl cyanoacrylates as in case of nanoparticles and microsheres. 
• Cell toxicity and ocular irritation caused by stearylamine positive 
liposomes.14 
 
            To overcome the above mentioned problems, an alternative approach of in situ 
gelling systems or phase transition systems which are instilled in a liquid form and 
shift to a gel or solid phase in cul-de-sac by change in pH, temperature and 
electrolytes present is selected as a novel system.3 
            The aim of the current work is to formulate and evaluate the pH-triggered in 
situ gelling system to deliver sustained drug release.Due to the gelling capacity of the 
pH-triggered in situ gelling system after instillation in to the eye by increase in pH of 
tear fluid, the drainage of formulation is minimal compared to conventional 
ophthalmic eye drops.   
            The in situ gelling system provides longer contact time and sustained delivery 
of the drug, hence decrease in frequency of administration and improved patient 
compliance are the major advantages. The ocular conjunctivitis caused by various 
micro organism causes permanent conjunctival damages, corneal ulceration, systemic 
infections. The role of topical quinolones reserved principally for severe bacterial 
conjunctivitis.22 
            The second generation flouroquinolone, levofloxacin 0.5% solution is 2 times 
potent than the ofloxacin ophthalmic solution and hence selected as a drug in the 
formulation of pH-triggered in situ gelling system. 
            The formulation of pH-triggered in situ gelling system would be a alternative 
to conventional marketed eye drops by providing sustained drug release and improved 
patient compliance due to less frequency in administration. 
Chapter V                                                                                                        Plan of Work 
 40
 
CHAPTER V 
PLAN OF WORK 
1. Determination of λmax of levofloxacin hemihydrate 
2. Calibration curve for the drug in simulated tear fluid pH 7.4 
3. Formulation of levofloxacin in situ gelling system by using different concentrations of     
    Carbopol 940 and HPMC (k4m, E50LV, E15LV) by pH-triggered in situ gelling 
system 
4. Determination of gelling capacity 
5. Sterilization by autoclave at 121◦C and 15 p.s.i for 15 minutes. 
6. In –vitro release characteristics of pH-triggered in situ gelling system by using  
    simulated tear fluid pH7.4 
7. Rheological evaluation of pH-triggered in situ gelling system using different shear  
    stress starting from  0.01,0.1,0.5,1.0,5.0,10,20,50,75 to 100 rpm. 
8. Sterility test for selected formulation. 
9. Evaluation of formulation for anti-microbial activity for selected formulation by using  
    different strains of micro-organisms. 
 10. Comparisons of In –vitro release pattern of pH-triggered in situ gelling system with  
       marketed formulation of eye drops. 
11. Accelerated stability studies of pH-triggered in situ gelling system. 
12. Ocular irritancy test of selected formulation of in situ gelling system on rabbit eye by  
       using modified Draize protocol. 
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CHAPTER VI 
 
MATERIALS AND EQUIPMENTS 
 
 
 
MATERIALS USED 
 
1. Drug- Levofloxacin hemihydrate           -Shasun laboratories 
 
2. Poly acrylic acid(Carbopol 940)     - Shasun laboratories 
 
3. Hydroxy propyl methyl cellulose(k4m)        - Shasun laboratories 
 
4. Hydroxy propyl methyl cellulose(E50LV)        - Shasun laboratories 
 
5. Hydroxy propyl methyl cellulose(E50LV)     - Shasun laboratories 
 
6. Tween 20                                                        - S.D.Fine chem Ltd 
 
7. Benzalkonium chloride                 - Nice chemicals 
 
8. Di-sodium hydrogen phosphate      - Vin biotech systems  
                                                                                        
9. Citric acid                                                            - Nice chemicals                
                                                                                       
10.  Sodium chloride                    - Loba chemie 
 
11. Hydrochloric acid           - Nice chemicals 
 
12. Sodium hydrogen carbonate                     - Merck 
 
13. Calcium chloride                                 - Nice chemicals 
 
14. Sodium hydroxide           - Nice chemicals 
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EQUIPMENTS USED 
 
 
1. Mechanical stirrer                              - Bombay India ltd. 
 
2.  Brookfield viscometer                      - A.R. and Companies 
 
3. Electronic Balance            - A&D Company, Japan 
 
4. Magnetic Stirrer            - MC Dalal & co  
 
5. UV Visible Spectrophotometer          - UV Pharma spec 1700, Shimadzu 
 
6. FTIR Spectrophotometer                   - FTIR,Shimadzu 
 
9. Environmental chamber                      - Inlab equipments (Madras pvt ltd) 
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CHAPTER – VII 
DRUG PROFILE 
Levofloxacin: 
                            Levofloacin, is a synthetic broad-spectrum antibacterial agent and a 
chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug 
substance ofloxacin. The chemical name is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-
methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid 
hemi hydrate.23,24 
Structural form: 
 
 
 
Empirical formula:  
C18H20FN3O4 • ½ H2O  
Systematic IUPAC Name: 
Molecular Weight: 
370.38 
Description: 
               Levofloxacin is a light yellowish-white to yellow-white crystal or 
crystalline powder.  
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CHEMICAL PROPERTIES: 
Solubility: 
                          The data demonstrate that from pH 0.6 to 5.8, the solubility of 
levofloxacin is essentially constant (approximately 100 mg/mL). Levofloxacin is 
considered soluble to freely soluble in this pH range. Above pH 5.8, the solubility 
increases rapidly to its maximum at pH 6.7 (272 mg/mL) and is considered freely soluble 
in this range. Above pH 6.7, the solubility decreases and reaches a minimum value (about 
50 mg/mL) at a pH of approximately 6.9. 
 
Melting point:   218oc 
PKa:  
Partition co-efficient: 
CLINICAL PHARMACOLOGY 
Mechanism of action 
                                 Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone 
antimicrobial agent The antibacterial activity of ofloxacin resides primarily in the L-
isomer. The mechanism of action of levofloxacin and other fluoroquinolone 
antimicrobials involves inhibition of bacterial topoisomerase IV and DNA gyrase (both of 
which are type II topoisomerases), enzymes required for DNA replication, transcription, 
repair and recombination. 
Anti-bacterial spectram 
               The materials have broad spectrum antibacterial and antifungal powerfulfeatures, 
the majority of Enterobacteriaceae bacteria such   Klebsiellapneumoniae,Proteus is, typhoid 
Salmonella spp, Shigella species, some E. coli, and has strong antibacterial activity, part of 
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staphylococcus, streptococcus pneumonia,influenzabacillus,Pseudomonas aeruginosa, 
gonorrhea, and chlamydia have good antibacterial effect.  
 
Dosage and Administration 
                       Levofloxacin is applied topically to the eye as an ophthalmic solution.The 
recommended dosage of levofloxacin for the treatment of bacterial conjunctivitis is 1 or 2 
drops of 0.5% solution in the affected eyes every 2-hours upto 8 times for 2 days,then 1 
or 2 drops every 4-hours upto 4 times for next 5 days. 
Common adverse effects 
                         Transient decrease in vision,transient ocular blurring,ocular pain or 
discomfort,foreign body sensation,headache,fever,pharyngitis,and photophobia occur in 
1-3 % of patients. Allergic reactions, lid edema, ocular dryness, and ocular itching occur 
in less than 1% of patients. 
Contraindications 
                      Known hypersensitivity to levofloxacin, other quinolones, or any 
ingredients in the formulation. 
Drug Interactions 
                       The systemic absorption may occur following topical application of 
levofloxacin to the eye. The reported interactions with theophylline, caffeine, anti 
coagulants and cyclosporine. 
Indication 
                      Conjunctivitis & otitis media. 
Storage 
                     Levofloxacin should be stored between 15-30 C (59-86 F) 25,26,27,28,29 
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CHAPTER - VIII 
EXCIPIENTS PROFILE 
1) HYDROXY PROPYL METHYL CELLULOSE (K4M): 
Synonym:  
                 Hypromellose, Methocel 
Structure: 
                     
 
Structural Formula 
 
                 Where R is H, CH3, or CH3CH(OH)CH2 
 
Empirical formula:  
                   Partly O-methylated and O-(2-hydroxy propylated) Cellulose.  
Molecular weight:   
                   10 000 – 1 500 00 
Description:   
                 An odorless and tasteless, white or creamy-white fibrous or granular powder. 
Solubility:  
                                               Soluble in cold water, forming a viscous colloidal solution, practically 
insoluble in chloroform, ethanol (95 %) and ether, but soluble in mixtures of ethanol and 
dichloromethane and mixtures of water and alcohol.  
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Methoxyl content: 
                   19-24% 
Hydroxy propyl content: 
                     7-12% 
Functional Category:   
                  Coating agent, Film- former, stabilizing agent, Tablet binder, viscosity 
increasing agent. 
 
 Typical Properties 
          
                 Acidity/alkalinity: pH -5.5–8.0 for a 1% w/w aqueous solution. 
 
Ash:  
                    
                1.5–3.0%, depending upon the grade and viscosity. 
 
Autoignition temperature: 
 
                      3608C 
 
Density (bulk): 
 
                     0.341 g/cm3 
 
Density (tapped): 
         
                    0.557 g/cm3 
 
Density (true):  
 
                   1.326 g/cm3 
 
Melting point: 
 
                   Browns at 190–2008C; chars at 225–2308C. 
 
Glass transition temperature  
 
                   170–1808C. 
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Moisture content 
                   Hypromellose absorbs moisture from the atmosphere; the amount of water 
absorbed depends upon the initial moisture content and the temperature and relative 
humidity of the surrounding air 
 
Viscosity: 
         Methocel K4M Premium  - 4000 mPas 
 
Applications in Pharmaceutical Formulation or Technology 
 
                    Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations.In oral products, hypromellose is primarily used as a tablet  binder,(1) in 
film-coating,(2–7) and as a matrix for use in extended-release tablet formulations. 
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2) HYDROXY PROPYL METHYL CELLULOSE (E50LV): 
Synonym:  
              Hypromellose, Methocel 
Structure: 
                     
 
Structural Formula 
 
              Where R is H, CH3, or CH3CH(OH)CH2 
 
Empirical formula:  
               Partly O-methylated and O-(2-hydroxy propylated) Cellulose.  
Molecular weight:   
               10 000 – 1 500 00 
Description:   
               An odorless and tasteless, white or creamy-white fibrous or granular powder. 
Solubility:  
                                             Soluble in cold water, forming a viscous colloidal solution, practically insoluble 
in chloroform, ethanol (95 %) and ether, but soluble in mixtures of ethanol and 
dichloromethane and mixtures of water and alcohol.  
Methoxyl content: 
               19-24% 
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Hydroxy propyl content: 
                7-12% 
Functional Category:   
              Coating agent, Film- former, stabilizing agent, Tablet binder & viscosity 
increasing agent. 
 
 Typical Properties 
          
                Acidity/alkalinity: pH - 5.5–8.0 for a 1% w/w aqueous solution. 
 
Ash:  
                    
                1.5–3.0%, depending upon the grade and viscosity. 
 
Autoignition temperature: 
 
                3608C 
 
Density (bulk): 
 
                0.341 g/cm3 
 
Density (tapped): 
         
                0.557 g/cm3 
 
Density (true):  
 
                1.326 g/cm3 
 
Melting point: 
 
                Browns at 190–2008C; chars at 225–2308C. 
 
Glass transition temperature  
 
                  170–1808C. 
 
 
 
Moisture content 
                   Hypromellose absorbs moisture from the atmosphere; the amount of water 
absorbed depends upon the initial moisture content and the temperature and relative 
humidity of the surrounding air. 
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Viscosity: 
                      Methocel E50LV Premium  - 50 m Pas 
 
Applications in Pharmaceutical Formulation or Technology 
                    Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations.In oral products, hypromellose is primarily used as a tablet  binder,(1) in 
film-coating,(2–7) and as a matrix for use in extended-release tablet formulations. 
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3) HYDROXY PROPYL METHYL CELLULOSE(E15LV): 
Synonym:  
             Hypromellose, Methocel 
Structure: 
                     
 
Structural Formula 
 
             Where R is H, CH3, or CH3CH(OH)CH2 
 
Empirical formula:  
             Partly O-methylated and O-(2-hydroxy propylated) Cellulose.  
Molecular weight:   
             10 000 – 1 500 00 
Description:   
             An odorless and tasteless, white or creamy-white fibrous or granular powder. 
Solubility:  
                                           Soluble in cold water, forming a viscous colloidal solution, practically insoluble 
in chloroform, ethanol (95 %) and ether, but soluble in mixtures of ethanol and 
dichloromethane and mixtures of water and alcohol.  
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Methoxyl content: 
              19-24% 
Hydroxy propyl content: 
              7-12% 
Functional Category:   
              Coating agent, Film- former, stabilizing agent, Tablet binder, viscosity 
increasing agent. 
 
 Typical Properties 
          
              Acidity/alkalinity: pH - 5.5–8.0 for a 1% w/w aqueous solution. 
 
Ash:  
                    
              1.5–3.0%, depending upon the grade and viscosity. 
 
Autoignition temperature: 
 
              3608C 
 
Density (bulk): 
 
              0.341 g/cm3 
 
Density (tapped): 
         
              0.557 g/cm3 
 
Density (true):  
 
              1.326 g/cm3 
 
Melting point: 
 
              Browns at 190–2008C; chars at 225–2308C. 
 
Glass transition temperature  
 
                170–1808C. 
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Moisture content 
              Hypromellose absorbs moisture from the atmosphere; the amount of water 
absorbed depends upon the initial moisture content and the temperature and relative 
humidity of the surrounding air 
 
Viscosity: 
                  Methocel E15LV Premium  - 15 m Pas 
 
Applications in Pharmaceutical Formulation or Technology 
 
                    Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations.In oral products, hypromellose is primarily used as a tablet  binder,(1) in 
film-coating,(2–7) and as a matrix for use in extended-release tablet formulations. 
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4) CARBOMER (CARBOPOL 940) 
 
Structure: 
 
 
 
 
 Synonyms 
 
               Acritamer; acrylic acid polymer; Carbopol; carboxy polymethylene,polyacrylic 
acid; carboxyvinyl polymer; Pemulen;Ultrez. Chemical Name and CAS Registry Number 
Carbomer 
 
Empirical Formula and Molecular Weight 
 
             Carbomers are synthetic high-molecular-weight polymers of acrylic acid that are 
crosslinked with either allyl sucrose or allyl ethers of pentaerythritol. They contain 
between 56% and 68% of carboxylic acid (COOH) groups 104 400 g/mol for Carbopol 
940 have been reported. 
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Structural Formula 
       Carbomer polymers are formed from repeating units of acrylic acid. The monomer 
unit is shown above. The polymer chains are crosslinked with allyl sucrose or allyl 
pentaerythritol. 
 
Functional Category 
          Bioadhesive; emulsifying agent; release-modifying agent; suspending agent; tablet 
binder; viscosity-increasing agent. 
 
Applications in Pharmaceutical Formulation or Technology 
 
Carbomers are mainly used in liquid or semisolid pharmaceutical formulations as 
suspending or viscosity-increasing agents.Formulations include creams, gels, and 
ointments for use in ophthalmic,(5–7) rectal,(8–10) and topical preparations. 
 
Emulsifying agent  
 
          0.1–0.5 
 
Gelling agent  
 
          0.5–2.0 
 
Suspending agent 
 
          0.5–1.0 
 
Tablet binder 
 
          5.0–10.0 
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 Description 
            Carbomers are white-colored, ‘fluffy’, acidic, hygroscopic powders with a slight 
characteristic odor. 
 
Pharmacopeial Specifications 
            Carbomer 940 (0.5 w/v) — 40 000–60 000(a) 
 
Typical Properties 
Acidity/alkalinity 
            pH = 2.7–3.5 for a 0.5% w/v aqueous dispersion; 
            pH = 2.5–3.0 for a 1% w/v aqueous dispersion. 
 
Density (bulk) 
            1,.76–2.08 g/cm3 
Density (tapped):  
                1.4 g/cm3 
Glass transition temperature:  
                100–1058C 
Melting point 
                Decomposition occurs within 30 minutes at 2608C. 
Moisture content 
                Normal water content is up to 2% w/w.However, carbomers are hygroscopic 
and a typical equilibrium moisture content at 258C and 50% relative humidityis 8–10% 
w/w. The moisture content of a carbomer does notaffect its thickening efficiency, but an 
increase in the moisture content makes the carbomer more difficult to handle because it is 
less readily dispersed. 
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Particle size distribution 
               Primary particles average about 0.2 mm in diameter. The flocculated powder 
particles average 2–7 mm in diameter and cannot be broken down into the primary 
particles. Recently, a granular carbomer having a particle size in the range 180–425 mm 
has been introduced. Its bulk and tap densities are also higher than those of other 
carbomers. 
 
Solubility 
              Soluble in water and, after neutralization, in ethanol (95%) and glycerin. 
Although they are described as ‘soluble’, carbomers do not dissolve but merely swell to a 
remarkable extent, since they are three-dimensionally crosslinked microgels.  
 
 
Viscosity (dynamic)  
              Carbomers disperse in water to form acidic colloidal dispersions of low viscosity 
that, when neutralized,produce highly viscous gels. Carbomer powders should first be 
dispersed into vigorously stirred water, taking care to avoid the formation of indispersible 
lumps, then neutralized by the addition of a base.  
 
 
Stability and Storage Conditions 
 
             Carbomers are stable, hygroscopic materials that may be heated at temperatures 
below 1048C for up to 2 hours without affecting their thickening efficiency. However, 
exposure to excessive temperatures can result in discoloration and reduced stability. 
Complete decomposition occurs with heating for 30 minutes at 2608C. Dry powder forms 
of carbomer do not support the growth of molds and fungi. 
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CHAPTER IX 
EXPERIMENTAL DETAILS 
     
CALIBRATION CURVE FOR LEVOFLOXACIN HEMIHYDRATE 
 PREPARATION OF CALIBRATION MEDIUM       
 Simulated tear fluid or artificial tear fluid 
  Sodium chloride – 0.670g,sodium bi carbonate - 0.200g,calcium chloride - 0.008g 
is placed in 100ml volumetric flask and dissolved and make up to volume with distilled 
water.31 
Preparation of standard curve for levofloxacin hemihydrate 
  The standard stock solution of levofloxacin hemihydrate is prepared by 
dissolving a known amount of drug in sodium hydroxide solution and dilution with 
simulated tear fluid. From the above stock solution, different concentrations of 
5,10,15,20......50μg /ml is prepared in simulated tear fluid. The resulting solution is 
scanned in UV Spectrophotometer to find λmax and the absorbance is measured at λmax 
(288nm)32. The standard curve is plotted by taking concentration in X-axis and 
absorbance in Y-axis. The standard curve is used to estimate drug content and percentage 
drug release.  
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FORMULATION OF pH TRIGGERED IN SITU GELLING SYSTEM OF 
LEVOFLOXACIN 
Optimum concentration of polymers 
             Carbopol is a polyacrylic acid (PAA) polymer, which shows sol to gel transition 
in aqueous solution as the pH is raised above its pka of about 5.5.The concentration of 
PAA required to form stiff gels results in highly acidic solutions which are not easily 
neutrlised by buffering action of tear fluid.A reduction in PAA concentration without 
compromising gelling capacity and rheological property achieved by addition of viscosity 
enhancing polymer HPMC. 
             It is noted that carbopol concentration 0.2% (W/V) had free flowing properties 
and these composition could not form gel at physiological condition. On the other hand 
carbopol concentration above 0.5%(W/V) formed stiff gel even at pH 4.0.As the 
concentration of carbopol solution increased, the solution become highly acidic ,which 
may stimulate the eye tissues.33 
             Based on the work of Helene hagerstrom, the carbopol concentration was fixed 
from 0.25 %( W/V) to 0.5 %( W/V). The HPMC of different grades in concentration 
fixed form 0.5 %( W/V) to 1.5 %( W/V) and the formulations made.34  
             Various in situ gelling system of levofloxacin hemihydrate is prepared by 
utilizing the phase transition properties of hydroxy propyl methyl cellulose E15LV, 
E50LV, K4M grade and carbopol 940 in different ratios by using pH triggered in situ 
gelling system which is shown in table no. 2 
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SELECTION OF VEHICLE 
            The vehicle is selected based on the solubility and stability of the drug. The 
solubility of levofloxacin is starting from the pH 2.0 to pH 6.5 and maximum at 
pH6.2.The marketed formulation showed the pH 6.2.For these reasons the citrophosphate  
buffer pH 6.0 is selected as vehicle for levofloxacin. 
 
 PREPARATION OF pH-TRIGGERED IN SITU GELLING SYSTEM 
             Aqueous solutions of varying concentrations of Carbopol 940 and Hydroxy 
propyl methyl cellulose of different grades are prepared. 
             The buffer salts are dissolved in specified quantity of purified water. To this 
methocel (E15LV, E50LV, K4M) is added and allowed to hydrate. Carbopol 940 is 
sprinkled over this solution and allowed to hydrate overnight. 
             The solution is stirred with an overhead stirrer, Tween 20 added whilst stirring. 
Levofloxacin is dissolved in sodium hydroxide solution and pH is adjusted. 
Benzalkonium chloride (BKC) is then added and the solution is filtered. 
             The drug solution is added to the Carbopol – HPMC solution under constant 
stirring until a uniform solution is obtained. Purified water is then added to make up the 
volume to 100ml. 
             The formulations are filled in 5-ml capacity vials, closed with gray butyl rubber 
closures and sealed with aluminium caps for further evaluations. All the formulations are 
sterilized using autoclave at 121◦C and 15 p.s.i for 20 minutes.35 
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EVALUATION OF FORMULATED IN SITU GELLING SYSTEM 
 
  The formulated levofloxacin in situ gels are evaluated for clarity, pH 
measurement, gelling capacity, drug content measurement, rheological study, sterility 
test, in vitro release study, anti microbial activity, eye irritation testing and stability 
testing.  
 
Determination of visual appearance, clarity and color  
  The visual appearance, clarity and color of the in situ gel formulation is noted.36 
 
PH measurement  
             The pH of all the prepared in situ gelling system is measured by using pH 
meter.37,65 
 
Drug content analysis  
   
  Drug content of in situ gel is determined by taking 2ml of in situ gel containing a 
known amount of drug in a 100ml volumetric flask and diluted with simulated tear fluid 
of ph 7.4 to get the concentration of 10μg/ml. The standard solution of concentration 
10μg/ml is also prepared. Then the absorbance is measured at λmax (288nm) using 
simulated tear fluid as blank by UV-spectrophotometer to calculate the percentage drug 
content.38,39,41 
 
Gelling capacity   
             The prepared in situ gelling system is evaluated for gelling capacity in order to 
identify the composition suitable for use as in situ system./The in situ gelling system is 
mixed with simulated tear fluid in the proportion of 25:7(application volume 25µl.normal 
volume of tear fluid in the eye is 7µl).The gelation is assessed by visual examination of 
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gel formation and noting the time for gelation and the time taken for the formed gel to 
dissolve.39,40,41 
 
In vitro release studies 
             The drug release from the prepared formulation is studied by using a modified 
method reported earlier. The test solution was placed in a circular plastic cup of 2.5cm 
internal diameter and1.2cm depth. This was in turn placed on an inverted USP basket kept 
inside a 250-ml beaker. Dissolution medium of 200ml of simulated tear fluid is added and 
stirred with a magnetic bead. Temperature of 37±1◦C is maintained throughout the study. 
Samples of 1ml are withdrawn at regular intervals and make up to 10ml with simulated 
tear fluid and replaced with an equal volume of fresh medium. The drug release study of 
in situ gelling system is compared with that of marketed conventional formulation of eye 
drops. 
             The absorbance of the samples is measured atλmax (288nm)by UV- 
spectrophotometer using blank to calculate amount of drug release from in situ gel. The 
percentage of drug release is plotted against time to find the drug release pattern of all in 
situ gel preparation.42,43,44,45,68,70,71 
 
  Rheological studies 
             The relationship between contact time and the rheology is easily understood for 
viscosity enhanced ophthalmic solutions. It is noted from various literature that, the 
formulations before gelling should have a viscosity of 5 to 1000 m pa and after gelling in 
the eye, will have a viscosity from about 50-50,000m pa. Viscosity determinations of the 
prepared formulations are carried out by Brookfield synchroelectric viscometer(LVDV 
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Pro II),spindle S18(small sample adaptor) and the angular velocity increased from 
0.01,0.1,0.5,1.0,5.0,10,20,50,75 to 100 and measurements are noted.46,47, 48,49,51,52,53.54,66,67 
                   
Antimicrobial activity 
             Antimicrobial efficiency studies are carried out to ascertain the biological activity 
of sol-to-gel systems against microorganisms. This is determined by agar diffusion test 
employing “cup plate technique”. Sterile solution of marketed levofloxacin eye drops is 
used as a standard.The standard solution and the developed formulations(test solution)are 
poured into separate cups bored into sterile Muller Hinton Agar(MHA) previously seeded 
with organisms(Staphylococcus aureus and Pseudomonas aeruginosa). After allowing 
diffusion of solutions for two hours, the plates are incubated for 24 h at 37◦C.The zone of 
inhibition(ZOI)measured around each cup is compared with that of the 
standard.36,41,55,56,57,69 
  
Sterility testing 
             Sterility testing is carried out by incubating formulations for not less than 14 days 
at 30 to 35◦ c in case of fluid thioglycolate medium for bacteria and at 20 to 25◦c in case 
of soyabean-casein digest medium for fungi and observations made.38,41 
 
Ocular irritancy studies 
             Ocular irritation studies are performed on male albino rabbits weighing 1-
2kg.The modified Draize technique is designed for the ocular irritation potential of the 
ophthalmic product. According to Draize test ,the amount of  substance applied to the eye 
is normally  100 µl placed to the lower cul-de-sac and observed at the time interval of 
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1hr,24hrs,48hrs,72hrs,and 1 week after administration. The rabbits observed periodically 
for redness, swelling and watering of the eyes.37,39,46,58,59,60,61,64,72,73,74. 
 
 
Accelerated stability studies  
             The sol-to-gel systems are placed in amber colored vials and sealed with 
aluminium foil for a short term accelerated stability study at 40◦±2◦c and 75±5% RH as 
per International Conference on Harmonization states guidelines. Samples are analysed 
every 15 days for appearance, pH, gelling studies and drug content.37,41,49,50 
                             
FT-IR studies  
             The possibility of drug-excipient interactions are further investigated by FTIR. 
The FTIR graph of pure drug and combination of drug with excipient are recorded .The 
analysis is performed using KBR pellets.57,62,63. 
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CHAPTER IX 
RESULTS AND DISCUSSION 
                              
CALIBRATION CURVE OF LEVOFLOXACIN HEMIHYDRATE 
            Calibration curve of levofloxacin hemihydrate was done in simulated tear fluid 
pH-7.4.Levofloxacin hemihydrate shows λmax of 288nm in simulated tear fluid 
pH7.4.The correlation coefficient was 0.99929866.Hence, Levofloxacin hemihydrate 
obeys the beer’s law within the concentration range of 5 to 50μg/ml.Calibration plots of 
levofloxacin hemihydrate in simulated tear fluid was showed in table 1 and fig.1.The 
maximum absorbance showed in fig.2.  
 
FORMULATION OF pH-TRIGGERED LEVOFLOXACIN HEMIHYDRATE IN 
SITU GELLING SYSTEM 
            Eighteen formulations of levofloxacin hemihydrate in situ gelling systems were 
prepared by using various concentrations of carbopol 940 along with different grades of 
hydroxyl propyl methyl cellulose in different ratios by using pH triggered in situ gelling 
method. The drug concentration kept as constant for each formulation (25mg/5ml). 
                            
            The two main prerequisite of an in situ gelling system are viscosity and gelling 
capacity. The formulation should have an optimum viscosity so that will allow easy 
instillation into the eye as liquid and undergo a rapid sol-to-gel transition (triggered by 
rise in pH from 6.0 to 7.4).       
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EVALUATION OF FORMULATION 
Appearance and clarity 
 The appearance of the formulation was light yellow and the system was clear 
except for formulations F-3 and F-6. Terminal sterilization by autoclaving had no effect 
on the formulations. The haziness observed during autoclaving due to precipitation of 
HPMC at elevated temperature was found to disappear and the clarity was regained after 
overnight standing. The observations are showed in table no.3. 
 
pH measurements 
            The pH of all the formulations were noted and it was from the pH 6.0 to 6.4 and 
found to be satisfied and showed in table no.3 
 
Drug content 
            The drug content of all the formulations noted and found to be within the normal 
range. The values are showed in table no.4 
 
Gelling capacity 
             The viscosity and gelling capacity plays important role for in situ gelling system. 
The formulation should have an optimum viscosity for easy instillation into the eye as a 
liquid which undergo sol-to-gel transition. The gelling capacity of various formulation 
given in table no.4 
            Formulations F-1,F-2,F-3 prepared from Carbopol940(0.5%) and HPMC K4M,F-
7,formulations F-8,F-9 prepared from Carbopol 940(0.5%) and HPMC 
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E50LV,formulation F-15 prepared from Carbopol 940(0.5%) and HPMC E15LV showed 
better gelling capacity. The other formulations were not having desirable gelling capacity.  
 
In vitro release studies 
            The cumulative percentage drug release of formulations F-1 to F 18 given in table 
no.5. The order of release of drug from the formulations as follows, 
F-13> F-12>F-4> F-14> F-5> F-7 >F-6> F-8 >F-1> F-2> F-9> F-3 
            The above formulations showed drug release for 8-hrs period of time and 
remaining formulations released drug before 8-hrs and the cumulative percentage drug 
release of F-13:100.57%, F-12:99.89%, F-4:99.42%, F-14:97.03%, F-5:93.94%, F-
7*9.97%, F-6:89.51%, F-8:83.36%, F-1:80.88%, F-2:77.75%, F-9:75.06% and F-
3:64.78% respectively and considered to be suitable for novel pH-triggered in situ gelling 
system of levofloxacin. The in vitro release observations were in accordance with the 
Carbopol/HPMC system reported by Kumar and Himmestein (1995). 
            The formulation prepared from HPMC K4M [F-3(0.9%W/V)] and carbopol 
940(0.5%W/V) showed maximum controlled drug release of 64.78% followed by 
formulation prepared from HPMC E50LV [F-9(0.9%W/V)] and carbopol 
940(0.5%W/V)of drug release, followed by formulation prepared from HPMC K4M 
[F-2(0.9%W/V)] and carbopol 940(0.5%W/V) 77.75% at 8-hrs.  
            The cumulative percentage drug release of marketed formulation of levofloxacin 
eye drops was compared with that of the selected formulations prepared from different 
grades of HPMC (K4M, E50LV, E15LV) with Carbopol and the observations showed in 
table.5G and fig.no.9. 
            The formulations were selected based on sustained in drug release at 8-hrs period 
of time and the graph is shown in figures.3-8. 
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               Even formulation F-3 achieved maximum sustained release achieved, due to 
turbidity the formulation is not considered as best formulation. 
               From the results it was concluded that the polymer concentrations of both 
Carbopol 940 and different grades of HPMC with higher viscosity plays important role in 
the release of drug from the formulations. When the polymer concentration increases drug 
release decreases, and when polymer concentration decreases drug release from the 
formulation increases. 
               The in vitro release of in situ gelling system containing low concentrations of 
polymer showed increase in drug release and high concentrations of polymer decrease in 
drug release during initial sampling.  
               The initial fast release from the formulation could be explained based on the fact 
that these systems formulated in aqueous vehicle .The matrix formed on gellation was 
already hydrated and hence hydration and water permeation could no longer limit the 
drug release.  
               The eye drops formed opaque matrix immediately upon addition to the 
dissolution medium, due to increase in pH of the simulated tear fluid. Hence the release 
of drug from this matrix was possibly by diffusion and /or erosion of the matrix. 
                The combination of these processes seemed to result in the overall diffusion 
controlled release kinetics. The in vitro release conditions may be vary from those likely 
to be encountered when instillation into the eye. There were, the results showed that the 
formed gel had the ability to retain levofloxacin for the duration of the study (8hrs).  
                The cellulose derivatives like HPMC (K4M, E50LV, E15LV) with higher 
molecular weight dissolve in water and yield much more viscous solution in combination 
with carbopol 940.Thus increase in viscosity might have contributed to decrease in rate of 
drug release from the formulation. 
Chapter X                                                                                          Results & Discussion 
 70
                The formulations prepared from each grade of HPMC (F-2, F-9, F-15) selected 
for rheological evaluation. 
 
RHEOLOGICAL STUDIES                                      
                The viscosity of the selected formulations based on in vitro release showed in 
table no.6.The viscosity of all these formulations decreased as the shear rate increased, 
which showed the character of pseudoplastic fluid. 
              Formulation F-2 showed better pseudoplastic behavior compared to all three 
formulations. The formulation F-2 selected as best formulation out of all 18 formulations 
based on clarity, pH, gelling capacity, in vitro release and viscosity. The pseudoplastic 
behavior of formulations showed in figure no.6 and fig.10 
             The formulations were shear thinning and an increase in shear stress was 
observed with increase in angular velocity (Pseudoplastic rheology). The administration 
of ophthalmic preparation should influence as little as possible the pseudoplastic 
character of the precorneal tear film. At formulation pH (pH 6.0), the formulations were 
in a liquid state and exhibited low viscosity. At pH of tear fluid (pH 7.4) the solution 
transformed to gels with high viscosity.  
             During blinking the shearing force on the preparation is large. The ocular shear 
rate is ranging from 0.03 s during inter-blinking  periods to 4250 – 28500 s diring 
blinking, viscoelastic fluids with a viscosity that is high under conditions of low shear 
rate and low under conditions of high shear rate which is called as pseudoplastic fluid, is 
often preferred. 
               If the viscosity at high shear rate is too high, It result in irritation. On the other 
hand ,if viscosity is too low ,it will give rise to increased drainage. 
Chapter X                                                                                          Results & Discussion 
 71
               The pseudoplastic property of these formulations is in favour of sustaining 
drainage of drug from the conjunctival sac of the eye,also without blinking difficulty for 
undergoing shear thinning. The remaining evaluations are performed only for the selected 
formulation F-2. 
                                       
ANTIMICROBIAL ACTIVITY                             
             The zone of inhibition (ZOI) measured around each cup was compared with that 
of control (Standard and marketed formulation).The results were showed in table.7 and in 
fig.11.The in vitro efficacy study of selected in situ gelling formulation of levofloxacin 
retained its antimicrobial efficacy when formulated as an in situ gelling system compared 
with that of marketed formulation of levofloxacin eye drops and the drug was active 
against the selected strains of microorganism. 
             The diameter of zone of inhibition produced by formulation F-2 against both test 
organisms was equal to that produced by marketed eye drops. The anti-microbial activity 
of levofloxacin in situ gel formulation is probably due to a fairly rapid initial release of 
drug into the viscous solution formed by dissolution of gel, followed by formation of a 
drug reservoir that permits the drug to be released to the target site relatively slowly. 
 
FT-IR STUDIES 
             FT-IR spectrum of pure drug and mixture of drug and polymers and given in fig 
no. From this study it was observed that there were no significant changes between the 
spectrum of pure drug and the mixture. It showed that there were no specific interactions 
between the drug and excipients used in the formulations.  
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STERILITY TEST 
             The test for sterility is an important aspect for ophthalmic preparations. The test 
for sterility is intended for detecting the presence of viable bacteria, fungi and yeast in 
sterilized preparations and observations showed in table no.8 
             The formulation F-2 passed the test for sterility as there was no appearance of 
turbidity and hence no evidence of microbial growth when incubated for not less than 14 
days at 30-35◦c in case of fluid thioglycolate medium and at 20-25◦c in the case of 
soyabean casein digest medium.  
 
OCULAR IRRITANCY TEST 
             The observations of ocular irritancy were showed in table no.9. The ocular 
irritancy test was carried out in male albino rabbits by using modified Draize test. For this 
purpose F-2 formulation was tested by comparison with marketed formulation of 
levofloxacin eye drops. Ocular tolerability results showed no evidence of redness, 
swelling or lacrymation in rabbit eyes. The score for ocular presentations were 
determined as zero at all observations. 
                                          
STABILITY STUDIES 
             All the formulations did not showed any change in appearance, clarity, pH and 
color of the preparations. It was also noted that no change in gelation properties of the 
prepared in situ gelling system. 
              The drug content of the formulations was tested regular interval and there was no 
significant change in the drug content. From the stability studies it was observed that 
there was no significant change in any of the parameters evaluated. It was found that the 
formulated in situ gelling system is stable. The observations showed in table no.10. 
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CHAPTER XI 
SUMMARY AND CONCLUSION 
 
• The purpose of this research was to develop a novel ophthalmic in situ drug 
delivery system of levofloxacin hemihydrate to improve its poor ocular 
bioavailability. 
• The ocular in situ gel of levofloxacin hemihydrate was prepared by using carbopol 
940 and HPMC (K4M, E50LV and E15LV) by pH-triggered in situ gelling 
technique.  
• The broad spectrum antibacterial agent used in the treatment of ocular infections 
like conjunctivitis was successfully formulated in situ gelling system using 
0.5%W/V of levofloxacin. 
• The formulated in situ gelling system were characterized for appearance, color, 
pH, gelling capacity, rheological character, in vitro release in simulated tear fluid. 
• All the formulations were clear except, F-3 andF-6 and pH of the formulations 
was from 6-6.4. 
• The better gelling capacity was obtained by optimized concentrations of carbopol 
940 and HPMC when these two vehicles were combined, the gel strength and 
gelling capacity under physiological conditions were appropriate. 
• The formulations showed better gelling capacity which can be easily instill as a 
drop. 
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• The cumulative percentage of drug release of F-3 was 64.78% and F-2 was 
77.75%.The drug release of F-3 retarded much but the formulation was turbid, 
Hence the F-2,F-9,F-15 selected for evaluation of Rheological character. 
• The results of viscosity revealed that F-2 showed better pseudo plastic behavior in 
lowest concentration of HPMC k4m(0.6%W/V) than other formulations 
•  The in vitro release studies revealed that the increase in polymer concentration 
retards the drug release and the decrease of decrease in polymer concentration 
increases the drug release. 
• In order to achieve high stability all the formulations sterilized by autoclave at 
121c and 15 p.s.i for 20 minutes. The test for sterility showed no turbidity of the 
inoculated medium suggests that the pH activated in situ gelling system of 
levofloxacin was sterile.  
• The test for anti-microbial efficacy proved the formulation to be therapeutically 
efficacious. The comparison of anti-microbial activity of in situ gelling system 
with marketed formulation showed equal efficacy in zone of inhibition (ZOI). 
• The addition of benzalkonium chloride and autoclave sterilization of selected 
formulation F-2 had no influence on pH and viscosity. 
• The absence of irritant activity by animal study shows that the system is 
promising for ophthalmic use. 
• Stability studies indicated that the drug retention capacity of in situ gelling system 
was not changed significantly. 
• The FTIR results proved that no interactions between the drug and polymers of in 
situ gelling system. 
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• The methodology adopted for the in situ gelling system is cost effective 
• The pH-triggered in situ gelling system afforded sustained drug release over 8-h 
period of time. 
• The in situ gel forming system could have good patient compliance because it’s 
easy instillation. 
• These hydrogel in situ formulations are administered into the eye as a solution, 
rapidly forming a hydrogel that is able to withstand the shear forces in the cul-de-
sac. 
• The pH-triggered in situ gel of levofloxacin has sustained drug release than 
conventional ophthalmic solutions of levofloxacin, and which is a viable 
alternative to conventional eye drops by its ability to retard drug release. 
• The prolonged precorneal residence time of in situ gelling system to get higher 
bioavailability and reduced systemic side effects caused by prevention of drainage 
from the nasolacrymal duct makes the formulation advantages over conventional 
eye drops. 
• The pH triggered in situ gel of levofloxacin formulation was effective in treatment 
of conjunctivitis and the drug was released from the formulation in a constant 
manner for the desired period of time. 
• The in situ gelling formulation evaluated here has potential in ophthalmic use, for 
reason that it is more readily administered and hence the pH-triggered in situ 
gelling considered to be promising for prolonging the ocular residence time 
without causing irritation to eyes and a viable alternative to marketed eye drops. 
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          Comparison of invitro release profile of in situ gelling system containing various
concentration of HPMC E50LV in carbopol 0.5%
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           Comparison of invitro release profile of in situ gelling system containing various
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                      Comparison of in vitro release of selected in situ gel formulations (F2, F9, F15) and
marketed levofloxacin eye drops
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Determination of λ max of levofloxacin hemihydrate
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Comparison of antibacterial activity
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Calibration curve for levofloxacin hemihydrate in simulated tear fluid pH-7.4
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